Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
about
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerEfficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysisBevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trialsCardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.[Resistance to anti-angiogenic therapy: a clinical and scientific current issue].Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
P2860
Q26774789-BCD61704-1238-4953-8D75-46F8E0ED448EQ34545018-2F844105-4D9C-4519-BC87-F0043F5BBA88Q36167140-0ED88CBB-7A7E-4C98-AE99-61F92CB291DEQ38371293-F55993B5-934A-4C82-8898-AC9A974080DCQ38778205-51F2B2D6-47AE-4D88-892C-6E8B53A81229Q43202699-B62B78FD-3EC4-4A32-BCB5-4962A21B7232Q44096551-64A03497-0121-4240-996F-EDA0F9291E5FQ50872828-B1A1FC3B-9A49-46A2-A8B4-077E0F6ACA9DQ53787748-0F6620AA-ED69-44CC-8673-B19101DDDE4DQ53788954-548A9790-48B1-4C3D-AE61-82D1D90249D6Q55083555-E44BA20A-C981-4021-BC7E-76849EB80A65
P2860
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@ast
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@en
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@nl
type
label
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@ast
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@en
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@nl
prefLabel
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@ast
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@en
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@nl
P2093
P2860
P31
P921
P3181
P1433
P1476
Efficacy and Safety Assessment ...... f Randomized Controlled Trials
@en
P2093
Anke H Maitland-van der Zee
Anthonius de Boer
Fariba Ahmadizar
N Charlotte Onland-Moret
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0136324
P407
P50
P5008
P577
2015-09-02T00:00:00Z